Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the response rate in platinum-resistant, KRAS
wild-type, ovarian cancer patients who are treated with pegylated liposomal doxorubicin
(Caelyx®) in combination with biological treatment panitumumab (Vectibix®).